Trial Profile
Pharmacokinetics of the Intralesional administration with two doses of rhEGF (75 microg and 225 microg) in patients with advance Diabetic Foot Ulcers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs Recombinant epidermal growth factor (Primary)
- Indications Diabetic foot ulcer
- Focus Pharmacokinetics
- 18 Mar 2013 New trial record